Radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity

As the population ages, more elderly patients require radiotherapy-based treatment for their pelvic malignancies, including muscle-invasive bladder cancer, as they are unfit for major surgery. Therefore, there is an urgent need to find radiosensitising agents minimally toxic to normal tissues, inclu...

Full description

Bibliographic Details
Main Authors: Groselj, B, Ruan, J, Scott, H, Gorrill, J, Nicholson, J, Kelly, J, Anbalagan, S, Thompson, J, Stratford, M, Jevons, S, Hammond, E, Scudamore, C, Kerr, M, Kiltie, A
Format: Journal article
Published: American Association for Cancer Research 2017
_version_ 1797066321147461632
author Groselj, B
Ruan, J
Scott, H
Gorrill, J
Nicholson, J
Kelly, J
Anbalagan, S
Thompson, J
Stratford, M
Jevons, S
Hammond, E
Scudamore, C
Kerr, M
Kiltie, A
author_facet Groselj, B
Ruan, J
Scott, H
Gorrill, J
Nicholson, J
Kelly, J
Anbalagan, S
Thompson, J
Stratford, M
Jevons, S
Hammond, E
Scudamore, C
Kerr, M
Kiltie, A
author_sort Groselj, B
collection OXFORD
description As the population ages, more elderly patients require radiotherapy-based treatment for their pelvic malignancies, including muscle-invasive bladder cancer, as they are unfit for major surgery. Therefore, there is an urgent need to find radiosensitising agents minimally toxic to normal tissues, including bowel and bladder, for such patients. We developed methods to determine normal tissue toxicity severity in intestine and bladder in vivo, using novel radiotherapy techniques on a small animal radiation research platform (SARRP). The effects of panobinostat (PAN) on in vivo tumour growth delay were evaluated using subcutaneous xenografts in athymic nude mice. PAN concentration levels in xenografts, plasma and normal tissues were measured in CD1-nude mice. CD1-nude mice were treated with drug/irradiation combinations to assess acute normal tissue effects in small intestine using the intestinal crypt assay, and later effects in small and large intestine at 11 weeks by stool assessment and at 12 weeks by histological examination. In vitro effects of PAN were assessed by qPCR and of PAN, TMP195 and mocetinostat by clonogenic assay, and western blot. PAN resulted in growth delay in RT112 bladder cancer xenografts but did not significantly increase acute (3.75 days) or 12 weeks’ normal tissue radiation toxicity. Radiosensitisation by PAN was effective in hypoxic bladder cancer cells and associated with class I HDAC inhibition, and protein downregulation of HDAC2 and MRE11. Pan-HDAC inhibition is a promising strategy for radiosensitisation, but more selective agents may be more useful radiosensitisers clinically, resulting in fewer systemic side effects.
first_indexed 2024-03-06T21:40:47Z
format Journal article
id oxford-uuid:47d7a856-ac91-4b02-ab2a-1c64b1e02b83
institution University of Oxford
last_indexed 2024-03-06T21:40:47Z
publishDate 2017
publisher American Association for Cancer Research
record_format dspace
spelling oxford-uuid:47d7a856-ac91-4b02-ab2a-1c64b1e02b832022-03-26T15:22:28ZRadiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicityJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:47d7a856-ac91-4b02-ab2a-1c64b1e02b83Symplectic Elements at OxfordAmerican Association for Cancer Research2017Groselj, BRuan, JScott, HGorrill, JNicholson, JKelly, JAnbalagan, SThompson, JStratford, MJevons, SHammond, EScudamore, CKerr, MKiltie, AAs the population ages, more elderly patients require radiotherapy-based treatment for their pelvic malignancies, including muscle-invasive bladder cancer, as they are unfit for major surgery. Therefore, there is an urgent need to find radiosensitising agents minimally toxic to normal tissues, including bowel and bladder, for such patients. We developed methods to determine normal tissue toxicity severity in intestine and bladder in vivo, using novel radiotherapy techniques on a small animal radiation research platform (SARRP). The effects of panobinostat (PAN) on in vivo tumour growth delay were evaluated using subcutaneous xenografts in athymic nude mice. PAN concentration levels in xenografts, plasma and normal tissues were measured in CD1-nude mice. CD1-nude mice were treated with drug/irradiation combinations to assess acute normal tissue effects in small intestine using the intestinal crypt assay, and later effects in small and large intestine at 11 weeks by stool assessment and at 12 weeks by histological examination. In vitro effects of PAN were assessed by qPCR and of PAN, TMP195 and mocetinostat by clonogenic assay, and western blot. PAN resulted in growth delay in RT112 bladder cancer xenografts but did not significantly increase acute (3.75 days) or 12 weeks’ normal tissue radiation toxicity. Radiosensitisation by PAN was effective in hypoxic bladder cancer cells and associated with class I HDAC inhibition, and protein downregulation of HDAC2 and MRE11. Pan-HDAC inhibition is a promising strategy for radiosensitisation, but more selective agents may be more useful radiosensitisers clinically, resulting in fewer systemic side effects.
spellingShingle Groselj, B
Ruan, J
Scott, H
Gorrill, J
Nicholson, J
Kelly, J
Anbalagan, S
Thompson, J
Stratford, M
Jevons, S
Hammond, E
Scudamore, C
Kerr, M
Kiltie, A
Radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
title Radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
title_full Radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
title_fullStr Radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
title_full_unstemmed Radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
title_short Radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
title_sort radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
work_keys_str_mv AT groseljb radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT ruanj radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT scotth radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT gorrillj radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT nicholsonj radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT kellyj radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT anbalagans radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT thompsonj radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT stratfordm radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT jevonss radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT hammonde radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT scudamorec radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT kerrm radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity
AT kiltiea radiosensitationinvivobyhistonedeacetylaseinhibitionwithnoincreaseinearlynormaltissueradiationtoxicity